Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemzoparlimab Monotherapy and with Azacitidine in AML and MDS
NCT04202003Phase 2Completed
- Sponsor
- TJ Biopharma
- Start
- Mar 2020
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lemzoparlimab in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by TJ Biopharma. Started Mar 2020; status: completed.
02
Drugs
lemzoparlimab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04202003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04202003.